Ignite Creation Date:
2025-12-24 @ 6:37 PM
Ignite Modification Date:
2026-01-02 @ 10:54 AM
Study NCT ID:
NCT05392257
Status:
UNKNOWN
Last Update Posted:
2022-05-26
First Post:
2022-05-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
Sponsor:
Qingdao Central Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-05-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-05-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-22
First Submit QC Date:
None
Study First Post Date:
2022-05-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-22
Last Update Post Date:
2022-05-26
Last Update Post Date Type:
ACTUAL